TRV130 is an opioid drug that is under evaluation in human clinical trials for the treatment of acute severe pain. TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less ??-arrestin 2 recruitment and receptor internalization, it displays less adverse effects than morphine.